WO2024043643A1 - Il2 변이체 및 이를 포함하는 단백질 복합체 - Google Patents

Il2 변이체 및 이를 포함하는 단백질 복합체 Download PDF

Info

Publication number
WO2024043643A1
WO2024043643A1 PCT/KR2023/012348 KR2023012348W WO2024043643A1 WO 2024043643 A1 WO2024043643 A1 WO 2024043643A1 KR 2023012348 W KR2023012348 W KR 2023012348W WO 2024043643 A1 WO2024043643 A1 WO 2024043643A1
Authority
WO
WIPO (PCT)
Prior art keywords
variant
protein complex
antibody
protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2023/012348
Other languages
English (en)
French (fr)
Korean (ko)
Inventor
방효주
정용준
정성엽
박영진
강석찬
박봄
박상현
조선정
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mustbio Co Ltd
Original Assignee
Mustbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mustbio Co Ltd filed Critical Mustbio Co Ltd
Priority to EP23857675.5A priority Critical patent/EP4578871A1/en
Priority to AU2023330441A priority patent/AU2023330441A1/en
Priority to CN202380061464.0A priority patent/CN119790064A/zh
Priority to JP2025511613A priority patent/JP2025527694A/ja
Publication of WO2024043643A1 publication Critical patent/WO2024043643A1/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • IL2 variants and protein complexes containing them It relates to IL2 variants and protein complexes containing them, methods for producing them, and uses thereof.
  • Immune checkpoints are proteins on the surface of immune cells that cancer cells use to avoid attack by the immune system. Cancer cells express PD-L1 on the cell surface and bind to PD-1, a type of immune checkpoint for T cells. Inhibits T cell activation and cancer cell killing ability. Immune checkpoint inhibitors can solve some of the side effects and resistance problems of existing anticancer drugs that directly attack cancer cells by activating the body's immune system and allowing immune cells to selectively attack cancer cells. In addition, a number of immune checkpoint inhibitors have been approved for marketing, confirming their efficacy in various cancer types. However, the overall response rate (ORR) is around 30% on average, so there are still many problems to overcome. To overcome this, interleukin is considered important as a dual agent and co-administration with immune checkpoint inhibitors to increase the effectiveness of immune checkpoint inhibitors.
  • interleukin-2 is a 15.5 kDa globular glycoprotein that is 133 amino acids long and plays a central role in lymphocyte production, survival, and homeostasis.
  • IL2 is mainly biosynthesized by activated T cells, especially CD4+ helper T cells, to stimulate T cell proliferation and differentiation, and to produce cytotoxic T lymphocytes (CTL) and natural killer cells (CTL). Stimulates the production and proliferation of Natural Killer cells (NK cells). Therefore, IL2 can increase the lymphocyte population in vivo and increase the function of the immune cells, and treatment using IL2 is currently approved and used in patients with metastatic renal cell carcinoma and malignant melanoma.
  • Lymphocyte activation of IL2 involves 3 different receptors called IL-2 receptor ⁇ (IL2 receptor ⁇ , IL2R ⁇ ; CD25), IL-2 receptor ⁇ (IL2 receptor ⁇ , IL2R ⁇ ; CD122), and common cytokine receptor ⁇ (IL2R ⁇ ; CD132). Its action is mediated by binding to canine IL2 receptor (IL2R) combinations. The distribution of each subunit receptor is different for each cell, and the binding affinity to IL2 also differs greatly for each receptor. High-affinity IL2R is composed of a trimer of three subunits ( ⁇ , ⁇ , and ⁇ ), and the dimeric IL2 receptor composed of ⁇ and ⁇ subunits is called medium-affinity IL2R.
  • the dimeric intermediate-affinity IL2R binds IL2 with approximately 100-fold lower affinity than the trimeric high-affinity receptor, but the dimeric and trimeric IL2Rs are capable of transducing signals upon IL2 binding. Therefore, the ⁇ -subunit, CD25, is not essential for IL2 signaling. The ⁇ -subunit confers high affinity binding to its receptor, while the ⁇ -subunit and the ⁇ -subunit are important for signal transduction. Trimeric IL2 containing CD25 is expressed by regulatory T cells and endothelial cells. The trimeric IL2R is also transiently induced on conventional activated T cells, whereas the T cells express only the dimeric IL2R in the resting state (Nature Review Immunology. 2012 12:180-190).
  • Regulatory T cells are a group of T cells that regulate the immune system. They maintain tolerance to self-antigens, participate in autoimmune diseases, and generally induce the activation of effector T cells. It inhibits or downregulates proliferation, thereby impairing the effectiveness of cancer treatment. Regulatory T cells continuously express the highest level of CD25 and have a higher binding affinity for IL2 than effector T cells, which is an issue that hinders the efficacy of cancer treatment using IL2.
  • IL2 immunotherapy the side effects produced by recombinant human IL2 treatment are of concern.
  • Patients receiving high-dose IL2 therapy often experience systemic side effects, including severe cardiovascular, pulmonary, renal, hepatic, gastrointestinal, neurological, skin, and blood disorders, which require intensive monitoring and patient hospitalization.
  • the main causes of these side effects include vascular permeability leading to fluid extravasation in multiple organs (causing, for example, lung and skin edema and liver cell damage) and intravascular fluid depletion (causing a drop in blood pressure and compensatory heart rate increases).
  • VLS vascular leakage syndrome
  • VLS VLS was thought to be caused by the release of inflammatory cytokines, such as tumor necrosis factor (TNF)- ⁇ , from IL2-activated NK cells, but recently, IL2-induced pulmonary edema was found to be caused by pulmonary endothelial cells (low or low). or expressed a moderate level of trimeric IL2R) (International Immunology, 2006 vol. 18, no. 10:1461-1471).
  • TNF tumor necrosis factor
  • IL2 variants and their Fc (fragment crystallizable) region that selectively activate effector T cells are used to reduce toxicity and side effects and increase therapeutic efficacy.
  • Fc fragment crystallizable region
  • One aspect is providing a protein comprising an IL2 variant.
  • IL2 variants a first polypeptide comprising a first CH3 antibody constant region and a second polypeptide comprising a second CH3 antibody constant region; and an antibody or antigen-binding fragment thereof against an immune checkpoint inhibitor or an antibody or antigen-binding fragment thereof against a tumor associated antigen.
  • Another aspect is to provide a method of producing the protein or the protein complex.
  • Another aspect is to provide a pharmaceutical composition for preventing or treating cancer comprising the protein or protein complex as an active ingredient.
  • Another aspect is to provide a method of treating cancer comprising administering the protein or the protein complex.
  • Another aspect provides use of said protein or protein complex for the preparation of a cancer therapeutic agent.
  • One aspect is a protein comprising an IL2 variant, wherein the IL2 variant has glutamic acid (E), alanine (A), lysine (K), and Provided is a protein comprising one or more amino acids selected from the group consisting of serine (S).
  • E glutamic acid
  • A alanine
  • K lysine
  • S serine
  • the IL2 variant may be one in which one or more amino acids of wild-type IL2, including the amino acid of SEQ ID NO: 16, are substituted.
  • the IL2 variant may be one in which 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more amino acids are substituted, as long as IL2 activity is maintained.
  • the IL2 variant may be one in which one or more positions selected from the group consisting of 18, 19, 35, 38, 42, 125, and 126 of the wild-type IL2 amino acid, including the amino acid of SEQ ID NO: 16, are substituted.
  • the IL2 variant has methionine (M), arginine (R), alanine (A), and leucine (L) at one or more positions selected from the group consisting of 18, 19, 35, 38, 42, 125, and 126.
  • M methionine
  • R arginine
  • A alanine
  • L leucine
  • serine S
  • phenylalanine F
  • valine V
  • I glutamine
  • W tryptophan
  • W asparagine
  • N threonine
  • E glutamic acid
  • K lysine
  • K may contain one or more amino acids selected from the group consisting of
  • the IL2 variant may have increased or decreased binding affinity to the IL2 receptor due to amino acid substitution. For example, it may reduce binding affinity to IL2R ⁇ and/or IL2R ⁇ . Accordingly, the IL2 variant can selectively activate effector T cells compared to regulatory T cells that inhibit immune activity by IL2 by reducing the binding affinity to IL2R.
  • the IL2 variant may contain glutamic acid (E) at position 35, alanine (A) at position 38, lysine (K) at position 42, and serine (S) at position 125.
  • the IL2 variant has leucine (L), methionine (M), arginine (R), alanine (A), serine (S), and phenylalanine at one or more positions selected from the group consisting of 18 and 19.
  • L leucine
  • M methionine
  • R arginine
  • A alanine
  • S serine
  • T threonine
  • the IL2 variant may further include one or more amino acids selected from the group consisting of threonine (T) and isoleucine (I) at position 126.
  • T threonine
  • I isoleucine
  • the IL2 variant is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • an amino acid selected from the group consisting of threonine (T) and isoleucine (I).
  • the IL2 variant is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • L leucine
  • S serine
  • E glutamic acid
  • A alanine
  • K lysine
  • S serine
  • Valine (V) at position 18 isoleucine (I) at position 19
  • glutamic acid (E) at position 35 glutamic acid (E) at position 35
  • alanine (A) at position 38 glutamic acid (E) at position 35
  • alanine (A) at position 38 glutamic acid (E) at position 35
  • alanine (A) at position 38 lysine (K) at position 42 and serine (S) at position 125;
  • methionine (M) at position 18 methionine (M) at position 19, glutamic acid (E) at position 35, alanine (A) at position 38, lysine (K) at position 42, and serine (S) at position 125;
  • M methionine
  • F phenylalanine
  • E glutamic acid
  • A alanine
  • K lysine
  • S serine
  • E glutamic acid
  • A alanine
  • K lysine
  • S serine
  • T threonine
  • E glutamic acid
  • A alanine
  • K lysine
  • S serine
  • I isoleucine
  • the IL2 variant may include an amino acid selected from the group consisting of SEQ ID NOs: 1 to 15. Additionally, the IL2 variant may include a polynucleotide encoding the amino acid. Specifically, the polynucleotide may be selected from the group consisting of SEQ ID NOs: 56 to 70.
  • the protein may include an Fc region bound by a linker or carrier.
  • the linker may include 1 to 50 amino acids, albumin or a fragment thereof, and a copolymer such as polyethylene glycol.
  • the linker may include the amino acid sequence of SEQ ID NO: 18.
  • the Fc region is SEQ ID NO: 19 to 21; SEQ ID NOs: 22 to 24; SEQ ID NOS: 25 to 27; SEQ ID NOS: 28 to 30; SEQ ID NOS: 31 to 33; SEQ ID NOS: 34 to 36; SEQ ID NOs: 37 to 39; SEQ ID NOS: 40 to 42; SEQ ID NOs: 43 to 45; and SEQ ID NOs: 46 to 48; and may include one or more amino acid sequences selected from the group consisting of:
  • the protein may further include an antibody against an immune checkpoint inhibitor or an antigen-binding fragment thereof.
  • the immune checkpoint inhibitor may be, for example, PD-L1, PD-1, LAG3, VISTA, BTLA, TIM3, TIGIT, CTLA-4, etc.
  • the protein may further include an antibody against a tumor associated antigen or an antigen-binding fragment thereof.
  • the tumor-specific antigen may be, for example, PD-L1, EGFR, HER-2, B7H3, GPC3, CEA, TROP, PSMA, etc.
  • IL2 variants include IL2 variants; and an Fc region.
  • IL2 variants include IL2 variants; and a protein complex comprising an antibody against an immune checkpoint inhibitor or an antigen-binding fragment thereof.
  • IL2 variants include IL2 variants; and a protein complex comprising an antibody against a tumor associated antigen or an antigen-binding fragment thereof.
  • protein complex refers to a complex composed of two or more related polypeptides, and refers to an artificial recombinant protein expressed after linking the genes of one or more other proteins to the protein, and is referred to as “fusion protein.” It can be used interchangeably with .
  • the protein complex can be expected to have a synergistic effect on its function by connecting two or more proteins. Therefore, the protein complex is a complex, protein complex, or fusion protein containing an Fc region, and can selectively increase the activity of effector T cells compared to regulatory T cells by substituting specific amino acids in IL2.
  • the protein complex can effectively induce the death of cancer cells by specifically distributing in the tumor microenvironment, suppressing immune checkpoints, and activating immune cells. Compared to existing treatments, side effects are reduced and anticancer activity is maximized. A cure can be provided.
  • Another aspect includes a first polypeptide comprising a first CH3 antibody constant region and a second polypeptide comprising a second CH3 antibody constant region, wherein the first polypeptide and the second polypeptide form a heterodimer.
  • the N-terminus of at least one of the first or second polypeptides contains an antibody against an immune checkpoint inhibitor, an antigen-binding fragment thereof, an antibody against a tumor associated antigen, or
  • a protein complex comprising an antigen-binding fragment thereof, and comprising an IL2 variant at at least one of the N-terminus or C-terminus of the first or second polypeptide.
  • Figure 4 shows the structure of a protein complex containing an IL2 variant according to one embodiment.
  • the protein complex is an antibody against an immune checkpoint inhibitor or an antigen-binding fragment thereof, or an antibody against a tumor-specific antigen or an antigen thereof at the N-terminus of the first polypeptide containing the first CH3 antibody constant region.
  • the second polypeptide comprising a binding fragment and comprising a second CH3 antibody constant region may comprise an IL2 variant at the N-terminus.
  • the protein complex may contain an antibody against an immune checkpoint inhibitor, an antigen-binding fragment thereof, or a tumor at the N-terminus of a first polypeptide comprising a first CH3 antibody constant region and a second polypeptide comprising a second CH3 antibody constant region. It may include an antibody against a specific antigen or an antigen-binding fragment thereof, and may include an IL2 variant at the C-terminus of the first or second polypeptide.
  • the binding affinity between the antibody or antigen-binding fragment thereof against the immune checkpoint inhibitor and cancer cells or T cells is superior to that between T cells and the IL2 receptor. Therefore, the antibody or antigen-binding fragment thereof against the immune checkpoint inhibitor primarily binds to cancer cells or T cells surrounding cancer cells, thereby reducing the side effects caused by IL2 receptor binding, which can induce activation of immune cells throughout the body. You can.
  • the antibody or antigen-binding fragment thereof against the tumor-specific antigen not only binds specifically to cancer cells, but also has a superior binding affinity to cancer cells compared to the binding affinity between IL2 receptor binding proteins. Therefore, the antibody against the tumor-specific antigen or its antigen-binding fragment can primarily bind to cancer cells and reduce the side effects caused by IL2 receptor binding, which can induce the activation of immune cells throughout the body.
  • the antibody or antigen-binding fragment thereof against the immune checkpoint inhibitor and/or tumor-specific antigen may be, for example, an antibody, an antigen-binding fragment (Fab), a single chain variable fragment (scFv), or a nanobody. .
  • Fab antigen-binding fragment
  • scFv single chain variable fragment
  • nanobody nanobody
  • antibody is used interchangeably with “immunoglobulin (Ig).”
  • Ig immunoglobulin
  • a complete antibody has a structure of two full-length light chains and two full-length heavy chains, and each light chain is bound to the heavy chain through a disulfide bond (SS-bond).
  • the light chain is of two types, ⁇ and ⁇ , and is composed of approximately 211 to 217 amino acids.
  • Each human antibody contains only one light chain.
  • the light chain consists of a continuous constant region and a variable region.
  • ⁇ and ⁇ are composed of 450 amino acids
  • ⁇ and ⁇ are composed of 550 amino acids.
  • the heavy chain has two regions: a variable region and a constant region.
  • the variable region refers to a region in an antibody where an antigen binds.
  • the variable region may include a complementarity determining region (CDR) that provides antigen-binding specificity.
  • CDR complementarity determining region
  • the antibody may include a Fab (antigen-binding fragment) region that binds to an antigen and an Fc (fragment crystallizable) region that binds to a cell surface receptor.
  • Fab antibody-binding fragment
  • Fc fragment crystallizable region that binds to a cell surface receptor.
  • the Fab region is a polypeptide containing the heavy chain variable region (VH) domain and the heavy chain constant region 1 (CH1) domain, and the polypeptides of the light chain variable region (VL) domain and the light chain constant region (CL) domain linked by a disulfide bond. You can.
  • the Fc region may be a linkage of two polypeptides containing a heavy chain constant region 2 (CH2) domain and a constant region 3 (CH3) domain.
  • the Fc region may form a hinge region.
  • the CH3 antibody constant region refers to the heavy chain constant region 3 domain of the antibody.
  • the effector function of an antibody causes ADCC (antibody dependent cell cytotoxicity) or CDC (complement dependent cytotoxicity) by binding the Fc region to its receptor, the Fc ⁇ receptor, or to the complement (complement component) molecule C1q.
  • ADCC antibody dependent cell cytotoxicity
  • CDC complement dependent cytotoxicity
  • Immune cells have many Fc ⁇ receptors, which can induce the death of undesirable immune cells, so it is desirable to eliminate the effector function. Therefore, the CH3 antibody constant region may be modified to have high stability by reducing the binding force to the Fc ⁇ receptor or by having no or greatly reduced effector function. Additionally, the CH3 antibody constant region may be modified to reduce antibody-dependent cell-mediated toxicity (Antibody Dependent Cellular Cytotoxicity, ADCC).
  • the Fc region comprises tryptophan (W) at position 366 of the first CH3 antibody constant region, serine (S) at position 366, and alanine at position 368 of the second CH3 antibody constant region. (A), and valine (V) at position 407; and glycine (G) or phenylalanine (F) at position 351 of the second CH3 antibody constant region.
  • the Fc region includes serine (S) at position 366, alanine (A) at position 368, and valine (V) at position 407 of the first CH3 antibody constant region, and the second CH3 antibody constant region Contains tryptophan (W) at position 366 of the region; and glycine (G) or phenylalanine (F) at position 351 of the first CH3 antibody constant region.
  • the Fc region includes tryptophan (W) at position 366 of the first CH3 antibody constant region, glycine (G) at position 351, and serine (S) at position 366 of the second CH3 antibody constant region. , alanine (A) at position 368, and valine (V) at position 407; And it may include phenylalanine (F) or tryptophan (W) at position 351 of the first CH3 antibody constant region.
  • the Fc region has glycine (G) at position 351, serine (S) at position 366, alanine (A) at position 368, and valine (V) at position 407 of the first CH3 antibody constant region. It includes tryptophan (W) at position 366 of the second CH3 antibody constant region; and phenylalanine (F) or tryptophan (W) at position 351 of the second CH3 antibody constant region.
  • the first CH antibody constant region and the second CH antibody constant region include alanine (A), glycine ( It may further include one or more amino acids selected from the group consisting of G), glutamine (Q), phenylalanine (F), glutamic acid (E), and serine (S).
  • the CH antibody constant region may be a CH2 antibody constant region.
  • first CH2 antibody constant region and the second CH2 antibody constant region may be one in which leucine (L) at positions 234 and 235 is further substituted with alanine (A) (L234A/L235A).
  • leucine (L) at positions 234 and 235 is replaced with alanine (A), and proline (P) at position 329 is further replaced with glycine (G). It may be substituted (L234A/L235A/P329G).
  • first CH2 antibody constant region and the second CH2 antibody constant region are those in which asparagine (N) at position 297 is further substituted with alanine (A), glutamine (Q), or glycine (G) (N297A, N297Q or N297G).
  • first CH2 antibody constant region and the second CH2 antibody constant region have leucine (L) at positions 234 and 235 replaced with phenylalanine (F) and glutamic acid (E), and proline (P) at position 331. It may be further substituted with serine (S) (L234F/L235E/P331S).
  • first CH2 antibody constant region and the second CH2 antibody constant region have leucine (L) at positions 234 and 235 replaced with phenylalanine (F) and glutamic acid (E), and aspartic acid (D) at position 265. It may be further substituted with alanine (A) (L234F/L235E/D265A).
  • the Fc region is SEQ ID NO: 19 to 21; SEQ ID NOs: 22 to 24; SEQ ID NOS: 25 to 27; SEQ ID NOS: 28 to 30; SEQ ID NOS: 31 to 33; SEQ ID NOS: 34 to 36; SEQ ID NOs: 37 to 39; SEQ ID NOs: 40 to 42; SEQ ID NOs: 43 to 45; and SEQ ID NOs: 46 to 48; and may include one or more amino acid sequences selected from the group consisting of:
  • the first polypeptide or the second polypeptide; And the IL2 variant may be linked by a linker or carrier.
  • the linker includes an amino acid sequence of (GGGGS)n, and “n” may be a natural number from 1 to 10.
  • the linker may include the amino acid sequence of SEQ ID NO: 18.
  • the first polypeptide and the second polypeptide may form the Fc region of an antibody.
  • the heterodimer refers to a combination of two polypeptides with different sequences, numbers, or types of amino acid residues.
  • the protein complex may be a protein complex formed by combining two polypeptides that specifically bind to different targets.
  • the protein complex may be an antibody or an antigen-binding fragment thereof, a conjugate of a receptor and an agonist, a conjugate of a receptor and an antagonist, a conjugate of a receptor and a ligand, or a conjugate of a ligand and a decoy receptor.
  • the protein complex includes an antigen-binding fragment (Fab), a single chain variable fragment (scFv), an extracellular domain of a membrane receptor, an agonist, an antagonist, a ligand, a decoy receptor, and a cytoplasmic receptor. It may include one selected from the group consisting of kine, coagulation factor, and affinity tag.
  • the antibody may be, for example, IgA, IgD, IgE, IgG, or IgM.
  • the antibody may be a monoclonal antibody or a polyclonal antibody.
  • the antibody may be an animal-derived antibody, a mouse-human chimeric antibody, a humanized antibody, or a human antibody.
  • the term “antigen-binding fragment” refers to a fragment of the entire immunoglobulin structure and a portion of a polypeptide containing a portion to which an antigen can bind.
  • the antigen-binding fragment may be scFv, (scFv) 2 , Fv, Fab, Fab', Fv F(ab') 2 , or a combination thereof.
  • the term “receptor” refers to a substance that receives or transmits a signal that can be transmitted to a biological system.
  • the receptor may be a protein receptor.
  • the receptor can bind to an agonist, antagonist, ligand, or cytokine.
  • the agonist may be a substance that binds to a receptor and activates the receptor to induce a biological response.
  • the antagonist may be a substance that inhibits a biological response by binding to a receptor and inhibiting the receptor.
  • the ligand may be a substance that binds to a receptor.
  • the ligand can bind to a decoy receptor.
  • a decoy receptor refers to a receptor that specifically binds to a ligand and thereby inhibits signal transmission through the actual receptor.
  • the cytokine refers to a small protein that acts in cell signaling, regulation and maintenance of inflammatory processes.
  • the protein complex may be modified.
  • the protein complex may be modified by conjugation, binding, glycosylation, tagging, or a combination thereof.
  • the antibody can be conjugated with other drugs such as anticancer drugs.
  • the protein complex includes horseradish peroxidase (HRP), alkaline phosphatase, hapten, biotin, streptavidin, fluorescent substances, radioactive substances, quantum dots, and polyethylene glycol. : PEG), histidine tag, or a combination thereof may be combined.
  • the fluorescent substance may be Alexa Fluor®532, Alexa Fluor®546, Alexa Fluor®568, Alexa Fluor®680, Alexa Fluor®750, Alexa Fluor®790, or Alexa Fluor350.
  • the positions of amino acids in the Fc region or CH2, and CH3 regions are listed in the Kabat EU index ('Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991) According to the EU-index described in '.
  • the amino acid position and corresponding amino acid type of the CH3 domain are based on human IgG1.
  • Another aspect provides a polynucleotide encoding a protein according to one aspect or a protein complex according to another aspect.
  • the polynucleotide is one or more polynucleotides selected from the group consisting of SEQ ID NOs: 56 to 70; And it may include one or more polynucleotides selected from the group consisting of SEQ ID NOs: 74 to 76.
  • the polynucleotide is one or more polynucleotides selected from the group consisting of SEQ ID NOs: 56 to 70; A polynucleotide comprising SEQ ID NO: 73; And it may include one or more polynucleotides selected from the group consisting of SEQ ID NOs: 74 to 76.
  • the polynucleotide is one or more polynucleotides selected from the group consisting of SEQ ID NOs: 56 to 70; A polynucleotide comprising SEQ ID NO: 73; One or more polynucleotides selected from the group consisting of SEQ ID NOs: 74 to 76; And it may include one or more polynucleotides selected from the group consisting of SEQ ID NOs: 77 to 82.
  • Another aspect provides a method of producing a protein or protein complex comprising transforming an expression vector encoding a protein according to one aspect or a protein complex according to another aspect into a cell to express the protein or the protein complex.
  • another aspect provides a protein or protein complex comprising an IL2 variant prepared by the method.
  • An expression vector is an expression vector capable of expressing a target protein in a suitable host cell, and refers to a vector containing essential regulatory elements operably linked to express the inserted nucleic acid sequence.
  • operably linked means that the nucleic acid expression control sequence and the nucleic acid encoding the target protein are functionally linked to perform a general function.
  • the expression vector may contain a polynucleotide encoding the protein complex.
  • the expression vector may include regulatory regions necessary for gene expression, such as an enhancer, a promoter, and a poly(A) sequence.
  • the cells may be cancer cells.
  • the cells may be in vitro cells.
  • the cells may be bacteria, yeast, plant cells, or mammalian cells.
  • the bacteria may be Escherichia coli.
  • the mammalian cell refers to a cell derived from a mouse, rat, rabbit, dog, cat, sheep, cow, horse, monkey, chimpanzee, or human.
  • the cells may be cell lines.
  • the cells include, for example, Chinese hamster ovary (CHO) cells, human embryonic kidney (HEK) cells, baby hamster kidney (BHK) cells, NS0 cells, PER.C6 cells, selected from the group consisting of HeLa cells, Madin-Darby Canine Kidney (MDCK) cells, SP2/0 mouse myeloma cells, COS-7, and YB2/0 rat myeloma cells.
  • the CHO cells may be CHO DG44, CHO-K1, CHO-S, GS-CHO, or CHO DUKX (DXB11) cells.
  • the HEK cells may be HEK 293 cells.
  • Transformation refers to a method of inserting a specific nucleic acid fragment into the genome of a cell so that the inserted nucleic acid is expressed.
  • the method comprises an antibody against an immune checkpoint inhibitor, an antigen-binding fragment thereof, or a tumor-specific antigen at the N-terminus of at least one of the first or second polypeptides.
  • the method includes a first agent comprising an antibody against an immune checkpoint inhibitor, or an antigen-binding fragment thereof, or an antibody against a tumor associated antigen, or an antigen-binding fragment thereof at the N-terminus.
  • It may include the step of transforming two or more types of cells with an expression vector encoding a polypeptide and/or a second polypeptide and an expression vector encoding a first or second polypeptide containing IL2 at the N-terminus or C-terminus, respectively. You can.
  • the cells can be cultured in cell culture medium.
  • Cell culture medium refers to a solution containing nutrients necessary for cultivating cells.
  • the media includes commercial or manufactured media used to culture cells.
  • the cell culture medium may contain antibiotics.
  • the cell culture medium may contain G418 (geneticin), Puromycin, Blasticidin, Zeocin, or a combination thereof.
  • the cell culture medium may include a chemically defined medium.
  • the cells can be cultured under conditions that allow the cells to survive or proliferate. Conditions that allow survival or proliferation of the cells may vary depending on the type of cell.
  • the cells can be cultured at about 25°C to about 42°C, about 25°C to about 40°C, about 30°C to about 40°C, about 30°C to about 37°C, or about 37°C.
  • the cells can be cultured in the presence of air from about 1% CO 2 to about 10% CO 2 , or from about 5% CO 2 to about 10% CO 2 .
  • the cells can be cultured in a medium of about pH 6 to about pH 8, about pH 6.2 to about pH 7.8, about pH 6.4 to about pH 7.6, about pH 6.6 to about pH 7.4, or about pH 6.8 to about pH 7.2.
  • the cells may be cultured under dissolved oxygen conditions of about 10% to about 80%, about 15% to about 70%, or about 20% to about 60%.
  • the culture may vary depending on the type of cell.
  • the culture can be performed using known methods.
  • the culture can be performed on plates, flasks, etc.
  • the culture can be performed by attaching it to a substrate or suspending it in a culture medium.
  • the culture may be subculture, batch culture, fed-batch culture, perfusion culture, or a combination thereof.
  • the cell culture medium can be periodically exchanged with fresh medium.
  • the cells are cultured for about 1 day or more, about 2 days or more, about 3 days or more, about 4 days or more, about 5 days or more, about 6 days or more, about 1 week or more, about 10 days or more, about 2 weeks or more, about 3 days or more.
  • It may include obtaining a protein complex from the cells or cell culture medium.
  • the cell culture medium may be a culture medium without the cells.
  • an antibody against an immune checkpoint inhibitor, an antigen-binding fragment thereof, or a tumor associated antigen is attached to the N-terminus from the cell or cell culture medium.
  • a protein complex of a first polypeptide containing an antibody or an antigen-binding fragment thereof and a second polypeptide containing an IL2 variant at the N-terminus or C-terminus can be obtained.
  • an immune checkpoint inhibitor (immune checkpoint inhibitor) is added to the N-terminus from the cells or cell culture medium.
  • a first polypeptide comprising an antibody against an immune checkpoint inhibitor or an antigen-binding fragment thereof, or an antibody against a tumor associated antigen or an antigen-binding fragment thereof; and a second polypeptide comprising an IL2 variant at the N-terminus or C-terminus, respectively.
  • Obtaining the protein complex includes adding an antibody to an immune checkpoint inhibitor or an antigen-binding fragment thereof, or an antibody to a tumor associated antigen or an antigen-binding fragment thereof to the obtained N-terminus. It may include forming a protein complex by incubating the first polypeptide comprising the obtained second polypeptide comprising the IL2 variant at the N-terminus or C-terminus. The incubation may be performed under reducing conditions. The reducing conditions may be in the presence of 2-mercaptoethanol (2-ME), dithiothreitol (DTT), or a combination thereof.
  • 2-ME 2-mercaptoethanol
  • DTT dithiothreitol
  • Obtaining the protein complex may include purifying the protein complex.
  • the purification can be performed by filtration, centrifugation, chromatography, dialysis, immunoprecipitation, or a combination thereof.
  • Another aspect provides a pharmaceutical composition for preventing or treating cancer comprising a protein according to one aspect or a protein complex according to another aspect.
  • Another aspect provides use of a protein according to one aspect or a protein complex according to another aspect for the manufacture of a preventive or therapeutic agent for cancer.
  • the cancer may be a solid cancer or a non-solid cancer.
  • Solid cancer refers to cancerous tumors occurring in organs such as the liver, lungs, breast, and skin.
  • Non-solid cancer is cancer that occurs in the blood, and is also called blood cancer.
  • the cancer may be carcinoma, sarcoma, hematopoietic cell-derived cancer, germ cell tumor, or blastoma.
  • the above cancers include breast cancer, skin cancer, head and neck cancer, pancreatic cancer, lung cancer, colon cancer, colorectal cancer, stomach cancer, ovarian cancer, prostate cancer, bladder cancer, urethral cancer, liver cancer, kidney cancer, clear cell sarcoma, melanoma, cerebrospinal tumor, brain cancer, Thymoma, mesothelioma, esophageal cancer, biliary tract cancer, testicular cancer, germ cell tumor, thyroid cancer, parathyroid cancer, cervical cancer, endometrial cancer, lymphoma, myelodysplastic syndromes (MDS), myelofibrosis, acute leukemia, chronic leukemia , multiple myeloma, Hodgkin's disease, endocrine cancer, and sarcoma.
  • MDS myelodysplastic syndromes
  • prevention refers to any action that suppresses a disease or delays its onset by administering the pharmaceutical composition.
  • treatment refers to any action that improves or beneficially changes the symptoms of a disease by administering the pharmaceutical composition.
  • the pharmaceutical composition may include a pharmaceutically acceptable carrier.
  • the carrier is used to include an excipient, diluent, or auxiliary agent.
  • the carriers include, for example, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl chloride. It may be selected from the group consisting of rolidone, water, physiological saline, buffer solutions such as PBS, methyl hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate, and mineral oil.
  • the composition may include fillers, anti-coagulants, lubricants, wetting agents, flavoring agents, emulsifiers, preservatives, or combinations thereof.
  • the pharmaceutical composition can be prepared in any dosage form according to conventional methods.
  • the composition may be formulated, for example, as an oral dosage form (e.g., powder, tablet, capsule, syrup, pill, or granule), or a parenteral dosage form (e.g., injection). Additionally, the composition may be prepared as a systemic formulation or a topical formulation.
  • the pharmaceutical composition may further include other anticancer agents.
  • the anticancer drugs include cetuximab, Panitumumab, erlotinib, Gefitinib, trastuzumab, T-DM1, Perjeta, and lapatinib. ), paclitaxel, taxol, tamoxifen, cisplatin, or a combination thereof.
  • the pharmaceutical composition may be a single composition or separate compositions.
  • the composition of the antibody or antigen-binding fragment thereof may be a composition in a parenteral dosage form
  • the anticancer agent may be a composition in an oral dosage form.
  • the pharmaceutical composition may include the protein complex in an effective amount.
  • effective amount means an amount sufficient to produce a preventive or therapeutic effect when administered to an individual in need of prevention or treatment of a disease.
  • the effective amount can be appropriately selected by a person skilled in the art depending on the cell or organism selected. Factors including the severity of the disease, the patient's age, weight, health, gender, the patient's sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, drugs combined or used simultaneously with the composition used, and other fields of medicine. It can be determined according to well-known factors.
  • the effective amount may be about 0.5 ⁇ g to about 2 g, about 1 ⁇ g to about 1 g, about 10 ⁇ g to about 500 mg, about 100 ⁇ g to about 100 mg, or about 1 mg to about 50 mg per pharmaceutical composition. there is.
  • the dosage of the pharmaceutical composition may be, for example, about 0.001 mg/kg to about 100 mg/kg, about 0.01 mg/kg to about 10 mg/kg, or about 0.1 mg/kg to about 1 mg/kg, based on adults. It may be within the range of kg.
  • the administration may be administered once a day, multiple times a day, or once a week, once every two weeks, once every three weeks, or once every four weeks to once a year.
  • Another aspect provides a method for preventing or treating cancer comprising administering a protein according to one aspect or a protein complex according to another aspect to a cell or subject.
  • the subject may be a mammal, such as a human, cow, horse, pig, dog, sheep, goat or cat.
  • the individual may be an individual who suffers from or is likely to suffer from cancer.
  • the method may further include administering a second active ingredient to the subject.
  • the second active ingredient may be an active ingredient for preventing or treating cancer.
  • the active ingredient may be administered simultaneously, separately, or sequentially with the protein complex.
  • the protein or protein complex may be administered to the subject by any means, such as, for example, oral, intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal or subcutaneous administration. Can be administered directly.
  • the protein complex can be administered systemically or topically, alone or in combination with other pharmaceutically active compounds.
  • the preferred dosage of the protein or protein complex varies depending on the patient's condition and weight, degree of disease, drug form, administration route and period, but can be appropriately selected by a person skilled in the art.
  • the dosage is, for example, in the range of about 0.001 mg/kg to about 100 mg/kg, about 0.01 mg/kg to about 10 mg/kg, or about 0.1 mg/kg to about 1 mg/kg based on adults. It can be.
  • the administration may be administered once a day, multiple times a day, or once a week, once every two weeks, once every three weeks, or once every four weeks to once a year.
  • a protein according to one aspect may selectively increase the activity of effector T cells compared to regulatory T cells by substituting a specific amino acid sequence of IL2.
  • the pharmaceutical composition containing the protein can reduce side effects and maximize anticancer activity compared to existing treatments, so it can be used for the prevention or treatment of cancer.
  • Figure 1a shows the results of purifying the PD-L1 antibody-IL2 variant 2 protein complex according to one embodiment using the Protein-A affinity column purification method.
  • Figure 1b shows the results of purifying the PD-L1 antibody-IL2 variant 2 protein complex according to one embodiment using a cation exchange resin column purification method.
  • Figure 1c shows the results of purity analysis of the PD-L1 antibody-IL2 variant 2 protein complex according to one embodiment through SE-HPLC analysis.
  • Figure 2a shows the results of comparing the anticancer effect in colon cancer transplant mice of the PD-L1 antibody-IL2 variant 2 protein complex and the positive control group (Avelumab, and combined administration of Avelumab and Aldesleukin) and the negative control group according to one embodiment.
  • Figure 2b shows the results of confirming the individual cancer cell growth inhibition and complete remission activity of the PD-L1 antibody-IL2 variant 2 protein complex according to one embodiment in mice transplanted with colon cancer.
  • Figure 2c shows the results of confirming the individual cancer cell growth inhibition and complete remission effects of the negative control group and positive control group (Avelumab, and combined administration of Avelumab and Aldesleukin) in mice transplanted with colon cancer.
  • Figure 3 shows the results confirming the anticancer effect of the PD-L1 antibody-IL2 variant 4 protein complex in colon cancer transplant mice according to one embodiment.
  • Figure 4 shows the structure of a protein complex containing an IL2 variant according to one embodiment.
  • Figure 5a shows the results of purifying the mousePD-1 antibody-IL2 variant 14 protein complex (a+c) according to one embodiment using the Protein-A affinity column purification method.
  • Figure 5b shows the results of purifying the mousePD-1 antibody-IL2 variant 14 protein complex (a+c) according to one embodiment using a hydrophobic interaction column purification method.
  • Figure 5c shows the purity analysis results of the mousePD-1 antibody-IL2 variant 14 protein complex (a+c) according to one embodiment.
  • Figure 6a shows the results of comparing the anticancer effects of mousePD-1 antibody-IL2 variant 14 protein complex (a+c), negative control group, and positive control group according to one embodiment in a colon cancer transplant mouse model.
  • Figure 6b compares the change in body weight of the colon cancer transplant mouse model after administering the mousePD-1 antibody-IL2 variant 14 protein complex (a+c), negative control group, and positive control group according to one embodiment to the colon cancer transplant mouse model. This is one result.
  • An IL2 mutant was prepared by substituting amino acids at some positions among the wild-type IL2 amino acids (SEQ ID NO: 16). Specifically, a polynucleotide coding for an IL2 variant tagged with 6 An expression vector expressing the mutant was prepared. Each amino acid substitution site and substituted amino acid in the IL2 variant are shown in Table 1 below. Afterwards, the expression vector was transfected into the ExpiCHO-S TM cell line using the ExpiFectamine TM CHO Transfection kit (ThermoFisher). The transfected cells were cultured at 32°C in a 5% CO 2 incubator at 120 rpm for 12 days. After 12 days, the culture supernatant was separated and recovered and filtered through a sterile filter to obtain IL2 variant protein.
  • E A K S IL2 variant 1 E A K S IL2 variant 2 E A K S M S IL2 variant 3 E A K S A S IL2 variant 4 E A K S R S IL2 variant 5 E A K S M L IL2 variant 6 E A K S L S IL2 variant 7 E A K S S W IL2 variant 8 E A K S F N IL2 variant 9 E A K S V I IL2 variant 10 E A K S I T IL2 variant 11 E A K S Q A IL2 variant 12 E A K S M M IL2 variant 13 E A K S M F IL2 variant 14 E A K S T IL2 variant 15 E A K S I
  • Example 1-1 the culture medium obtained in Example 1-1 was centrifuged and separated into cultured cells and medium. Afterwards, the IL2 variant protein in the separated medium was filtered through a 0.22 ⁇ m filter (Thermo Scientific) to remove fine debris. The filtered medium was first purified using imidazole affinity chromatography (Ni-SepFast, Biotoolomics), and then the imidazole buffer component present in the purified product was removed through desalting and concentration processes. Afterwards, the content and purity of the final purified product were analyzed.
  • imidazole affinity chromatography Ni-SepFast, Biotoolomics
  • Example 1-2 Activation of the IL2 variant-protein complex purified in Example 1-2 was confirmed on human immune cells. Specifically, human peripheral blood mononuclear cells (Stem cell), effector CD8+ T cells (CD3+, CD8+), and Treg cells (CD4+, CD25+) were reacted with a specifically fluorescently labeled antibody at 4°C for 30 minutes, shielded from light. , Antibodies not attached to the cells were removed by centrifugation. Thereafter, the IL2 variant 2, 4, and 14 proteins purified in Example 1-2 were treated and reacted at 37°C for 20 minutes, blocked from light, and fixed with 1 mL of Fixation buffer (BD, U.S.) for 12 minutes.
  • Fixation buffer BD, U.S.
  • Aldesleukin Proleukin, Novartis, Switzerland
  • each drug was treated at a concentration of 0.01 to 8,000 nM.
  • the cytoplasm of fixed human peripheral blood mononuclear cells was treated with 1.5 mL of Perm3 buffer (BD, U.S.) and reacted at 4°C for 35 minutes to allow the fluorescent label to penetrate into the cytoplasm, followed by phosphorylation.
  • STAT-5 and Foxp3+ protein, a Treg cell marker were fluorescently labeled and reacted for 30 minutes.
  • the degree of STAT-5 phosphorylation in effector CD8+ T and Treg cells in the group treated with the IL2 variant protein was compared through flow cytometry.
  • the positive control group (Aldesleukin) showed an EC 50 value ratio of CD8+ T cells/regulatory T cells of 16.3, indicating that it induced the activity of T reg cells more strongly than CD8+ T cells. I was able to confirm.
  • IL2 variant 2, 4, and 14 proteins showed EC 50 value ratios of CD8 + T cells/regulatory T cells of 0.6, 0.56, and 5.6, respectively, thereby more selectively activating CD8 + T cells compared to the positive control group. I was able to confirm that it was activated.
  • Fc protein complexes containing IL2 variants were prepared. Specifically, a polynucleotide encoding the Fc region was synthesized using ThermoFisher Scientific's Invitrogen GeneArt Gene Synthesis service, and then inserted into the AvrII-BstZ17I enzyme site of the pCHO1.0 expression vector to create a first expression vector expressing the Fc region. Manufactured.
  • AvrII-BstZ17I of the pCHO1.0 expression vector A second expression vector expressing IL2 variant-Fc was prepared by inserting it into the enzyme site. Afterwards, the first and second expression vectors were mixed 1:1 using the ExpiFectamineTM CHO Transfection kit (ThermoFisher), and then transfected into the ExpiCHO-STM cell line. The transfected cells were cultured at 32°C in an 8% CO 2 incubator at 125 rpm for 12 days. After 12 days, the culture supernatant was separated and recovered and filtered through a sterile filter to obtain a protein complex containing Fc and IL2 variant-Fc.
  • the IL2 variant-Fc protein complex obtained through culturing the cell line prepared in Example 2-1 was purified to obtain a highly purified material.
  • Example 2-1 the culture medium obtained in Example 2-1 was centrifuged and separated into cultured cells and medium. Afterwards, fine debris was removed from the IL2 variant-Fc protein complex in the separated medium using a 0.22 ⁇ m filter (Thermo Scientific).
  • the filtered medium was first purified using Protein A affinity chromatography (MabSelect PrismA, Cytiva). Specifically, after adding the filtered medium to the Protein-A column stabilized with Phosphate buffer saline (pH 7.4) buffer, non-specifically bound proteins were washed away using the same buffer, and then washed with the same buffer, pH 5 containing 0.02M Citric acid.
  • Proteins specifically binding to the Protein-A column were eluted along a pH gradient using two solutions of pH .0 and pH 3.5, and the sample was neutralized to pH 7.2 using 1 M Tris. Afterwards, the obtained IL2 variant-Fc protein complexes were stabilized with phosphate buffer saline (pH 7.4), and then the purified IL2 variant-Fc was obtained using size exclusion HPLC (TSK-3000SWxL, 7.8 mm x 30 cm, Tosoh). Purity analysis of the protein complex was performed.
  • Example 2-2 Activation of the IL2 variant-Fc protein complex purified in Example 2-2 on human immune cells was confirmed. Specifically, human peripheral blood mononuclear cells (Stem cell), effector CD8+ T cells (CD3+, CD8+), and Treg cells (CD4+, CD25+) were reacted with a specifically fluorescently labeled antibody at 4°C for 30 minutes, shielded from light. , Antibodies not attached to the cells were removed by centrifugation. Thereafter, the IL2 variant 1-Fc protein complex, IL2 variant 2-Fc protein complex, IL2 variant 4-Fc protein complex, and IL2 variant 14-Fc protein complex purified in Example 2-2 were treated and incubated at 37°C for 20 minutes.
  • the reaction was blocked from light and fixed with 1 mL of Fixation buffer (BD, U.S.) for 12 minutes.
  • Fixation buffer BD, U.S.
  • Aldesleukin Proleukin, Novartis, Switzerland
  • each drug was treated at a concentration of 0.01 to 8,000 nM.
  • the cytoplasm of fixed human peripheral blood mononuclear cells was treated with 1.5 mL of Perm3 buffer (BD, U.S.) and reacted at 4°C for 35 minutes to allow the fluorescent label to penetrate into the cytoplasm, followed by phosphorylation.
  • STAT-5 and Foxp3+ protein, a Treg cell marker were fluorescently labeled and reacted for 30 minutes.
  • the degree of STAT-5 phosphorylation in effector CD8+ T cells and Treg cells in the group treated with the IL2 variant-Fc protein complex was compared through flow cytometry.
  • the positive control group (Aldesleukin) showed an EC 50 value ratio of CD8+ T cells/regulatory T cells of 33.3, indicating that it induced the activity of T reg cells more strongly than CD8+ T cells. I was able to confirm.
  • IL2 variant 1-Fc protein complex had a ratio of EC 50 values of CD8 + T cells/regulatory T cells of 0.79. to 3.2, it was confirmed that the activity of CD8+ T cells was activated more selectively compared to the positive control group.
  • the IL2 variant according to one aspect can maintain the characteristic of activating CD8+ cells more selectively than regulatory T cells even in a structure to which Fc is added.
  • a protein complex containing PD-L1 antibody and IL2 variant was prepared. Specifically, using the same service as Example 2-1, a polynucleotide encoding a PD-L1 antibody heavy chain variable region-heavy chain constant region and a polynucleotide encoding a PD-L1 antibody light chain constant region-light chain variable region were produced, respectively. synthesized. Then, the polynucleotide encoding the PD-L1 antibody heavy chain variable region-heavy chain constant region and the polynucleotide encoding the PD-L1 antibody light chain constant region-light chain variable region were each added to the AvrII-BstZ17I enzyme site of the pCHO1.0 expression vector.
  • a first expression vector expressing PD-L1 antibody After synthesizing a polynucleotide encoding a complex containing a linker and an Fc region with any one of the IL2 variants 1 to 15 prepared in Example 1 using the same service, the AvrII-BstZ17I enzyme site of the pCHO1.0 expression vector A second expression vector expressing IL2 variant-Fc was prepared by inserting it into the . Thereafter, PD-L1 antibody containing anti-PD-L1 Fab-Fc and IL2 variant-Fc was produced in the same manner as in Example 2-1, except that the first and second expression vectors were used. -IL2 variant protein complex was obtained.
  • High purity material was obtained by purifying the PD-L1 antibody-IL2 variant 1 protein complex and the PD-L1 antibody-IL2 variant 15 protein complex obtained through culturing the cell line prepared in Example 3-1.
  • Example 3-1 the culture medium obtained in Example 3-1 was centrifuged and separated into cultured cells and medium. Afterwards, fine debris was removed from the PD-L1 antibody-IL2 variant protein complex in the separated medium using a 0.22 ⁇ m filter (Thermo Scientific).
  • the filtered medium was first purified using Protein A affinity chromatography (MabSelect PrismA, Cytiva). Specifically, after adding the filtered medium to the Protein-A column stabilized with Phosphate buffer saline (pH 7.4), proteins that did not bind non-specifically were washed away using the same buffer, and then washed with 0.05 M Citric acid (pH 3.9).
  • Proteins specifically binding to the Protein-A column were eluted using this buffer solution, and the sample was neutralized to pH 7.2 using 1 M Tris. Afterwards, the sample separated through the affinity column was subjected to secondary purification using cation exchange chromatography (Source30S, Cytiva) to remove any remaining impurities. Specifically, 1M Citric acid was added to the sample eluted and neutralized from the Protein-A column to titrate it to pH 6.0, and then placed on a Source30S column stabilized with 20 mM sodium phosphate (pH 6.0) buffer to remove proteins that did not bind non-specifically.
  • cation exchange chromatography Source30S, Cytiva
  • PD-L1 antibody-IL2 variant protein complexes were obtained by washing using the same buffer and eluting with an upward gradient using a buffer solution containing 0.3M NaCl (pH 6.0). Afterwards, the obtained PD-L1 antibody-IL2 variant protein complexes were stabilized with phosphate buffer saline (pH 7.4), and then the purified PD was obtained using size exclusion HPLC (TSK-3000SWxL, 7.8 mm x 30 cm, Tosoh). Purity analysis of the -L1 antibody-IL2 variant protein complex was performed.
  • Figure 1a shows the results of purifying the PD-L1 antibody-IL2 variant 2 protein complex according to one embodiment using the Protein-A affinity column purification method.
  • Figure 1b shows the results of determining the PD-L1 antibody-IL2 variant 2 protein complex according to one embodiment using a cation exchange resin column purification method.
  • Figure 1c shows the results of purity analysis of the PD-L1 antibody-IL2 variant 2 protein complex according to one embodiment through SE-HPLC analysis.
  • the protein that specifically binds to the column was confirmed by the elution buffer used in Protein-A affinity column purification. Specifically, a PD-L1 antibody-IL2 variant protein complex specifically binding to the column was confirmed in 1500 to 1550 ml of eluate.
  • the PD-L1 antibody-IL2 variant 2 protein complex obtained through Protein-A affinity column purification and cation exchange resin purification was confirmed to have a purity of 99% at a retention time of 16.717 minutes. there was.
  • the PD-L1 antibody-IL2 variant protein according to one aspect is purified with high purity.
  • the receptor binding ability of the PD-L1 antibody-IL2 variant protein complex was confirmed through SPR (Surface Plasmon Resonance) analysis. Specifically, human PD-L1, human IL2R ⁇ , IL2R ⁇ , and IL2R ⁇ were each immobilized on a CM5 sensor chip through covalent bonding, and then the PD-L1 antibody-IL2 variant 2 protein complex and PD prepared in Example 3-2 were added to the CM5 sensor chip. -L1 antibody-IL2 variant 4 protein complex was developed at various concentrations (serially diluted two-fold in the concentration range of 0.391 to 400 nM) to determine the binding kinetics for human PD-L1 and IL2 receptor (IL2R). were confirmed respectively.
  • SPR Surface Plasmon Resonance
  • binding affinity was calculated using the measured association constant (Ka) and dissociation constant (Kd) values.
  • Kd binding affinity
  • SPR sensogram analysis was performed using BIAlogue kinetics evaluation software. Avelumab and aldesleukin were used as positive controls, respectively, and the results are shown in Tables 4 and 5 below.
  • Figure 2a shows the results of confirming the binding ability of the PD-L1 antibody-IL2 variant 2 protein complex according to one embodiment to the human PD-L1 antigen.
  • Figure 2b shows the results confirming the binding ability of Avelumab to human PD-L1 antigen.
  • the PD-L1 antibody-IL2 variant 2 protein complex prepared in Example 3-2 and the positive control group were confirmed to bind to the human PD-L1 antigen.
  • the protein variant showed a binding affinity of 0.48 nM
  • the positive control showed a binding potency of 0.12 nM, which was confirmed to be about 4.1 times lower.
  • the positive control group is a single antibody and has a bivalent form of anti-PD-L1 arm, while the PD-L1 antibody-IL2 variant 2 protein complex has a monovalent form of anti-PD-L1 arm. It is thought that there is a difference in binding force because it has a PD-L1 arm.
  • the PD-L1 antibody-IL2 variant 2 protein complex prepared in Example 2 binds to IL2R ⁇ and IL2R ⁇ with binding affinities of 37.9 nM and 17.3 nM, respectively, but does not react with IL2R ⁇ . indicated.
  • the PD-L1 antibody-IL2 variant 2 protein complex bound to IL2R ⁇ and IL2R ⁇ with binding affinities of 23.8 nM and 30.6 nM, respectively, but did not react with IL2R ⁇ .
  • the PD-L1 antibody-IL2 variant 2 protein complex and the PD-L1 antibody-IL2 variant 4 protein complex according to one aspect did not bind to the IL2 receptor ⁇ .
  • the positive control group was confirmed to bind to IL2R ⁇ , IL2R ⁇ , and IL2R ⁇ with binding affinities of 35.7 nM, 1.55 nM, and 0.10 nM, respectively.
  • the binding affinity of the PD-L1 antibody-IL2 variant 2 protein complex and the PD-L1 antibody-IL2 variant 4 protein complex to IL2R ⁇ decreased by about 24.5-fold and 15.4-fold, respectively, compared to the positive control group.
  • the ratios of ⁇ / ⁇ of the PD-L1 antibody-IL2 variant 2 protein complex and the PD-L1 antibody-IL2 variant 4 protein complex were 2.19, respectively.
  • the positive control group showed 15.5, confirming that the ratio of IL2R ⁇ / ⁇ of the PD-L1 antibody-IL2 variant protein complex was significantly lowered compared to the positive control group.
  • the PD-L1 antibody-IL2 variant 2 protein complex and the PD-L1 antibody-IL2 variant 4 protein complex not only do not bind to IL2R ⁇ , but also their binding to IL2R ⁇ is weakened.
  • the PD-L1 antibody-IL2 variant protein complex is intended to induce higher activation in CD8 + T cells compared to regulatory T cells, and to selectively induce activation of CD8 + T cells expressing IL2R ⁇ . , the binding affinity to IL2R ⁇ is eliminated, and the binding affinity to IL2R ⁇ is adjusted through substitution of the specific amino acid.
  • the effects of PD-L1 antibody-IL2 variant 1 protein complex to PD-L1 antibody-IL2 variant 15 protein complex on the activation of human immune cells were confirmed.
  • human peripheral blood mononuclear cells stem Cell
  • CD8+ T cell CD3+, CD8+
  • regulatory T cell CD4+, CD25+, FoxP3+
  • Example 3-2 antibodies not attached to the cells were removed by centrifugation, and then the PD-L1 antibody-IL2 variant 1 protein complex to PD-L1 antibody-IL2 variant 15 prepared in Example 3-2 was added to human peripheral blood mononuclear cells. Protein complexes were treated at different concentrations (0.001 to 8000 nM), reacted at 37°C for 20 minutes, blocked from light, and fixed with 1 mL of Fixation buffer (BD, U.S.) for 12 minutes. In order to fluorescently label phosphorylated STAT-5 in the cytoplasm, 1.5 mL of Perm3 buffer (BD, U.S.) was treated and reacted at 4°C for 40 minutes to allow the fluorescent label to penetrate.
  • Fixation buffer BD, U.S.
  • the phosphorylated STAT-5 protein was fluorescently labeled and reacted for 30 minutes, and then the percentage of cells in which STAT-5 was phosphorylated in effector CD8+ T and regulatory T cells was confirmed through FACS analysis.
  • Aldesleukin Proleukin, Novartis, Switzerland
  • PD-L1 antibody-IL2 variant 8 protein complex 18.11 52.15 PD-L1 antibody-IL2 variant 9 protein complex 0.38 0.29 PD-L1 antibody-IL2 variant 10 protein complex 1.78 1.01 PD-L1 antibody-IL2 variant 11 protein complex 10.6 1.71 PD-L1 antibody-IL2 variant 12 protein complex 0.27 0.37 PD-L1 antibody-IL2 variant 13 protein complex 0.45 0.49 PD-L1 antibody-IL2 variant 14 protein complex 0.75 0.53 PD-L1 antibody-IL2 variant 15 protein complex 11.57 3.25
  • the ratio of EC 50 values of CD8+ T cells/regulatory T cells in the positive control group and PD-L1 antibody-IL2 comparison group was 62.9 and 22, respectively, and Example 3-2 above.
  • the ratio of EC 50 values of CD8+ T cells/regulatory T cells of the PD-L1 antibody-IL2 variant 1 protein complex to the PD-L1 antibody-IL2 variant 15 protein complex prepared in was 0.16 to 2.88.
  • the PD-L1 antibody-IL2 variant protein complex may participate in an immune response related to an anticancer effect by inducing the activity of effector T cells more strongly than regulatory T cells.
  • the anticancer activity of the PD-L1 antibody-IL2 variant protein complex was confirmed. Specifically, MC38 cells (1 did. Five days after inoculation, the PD-L1 antibody-IL2 variant 2 protein complex prepared in Example 3-2 was administered intraperitoneally at doses of 8 mg/kg and 16 mg/kg, respectively, Q2D x 2 times. After administration of the complex, tumor volume in mice was measured (3 times/week) to compare anticancer activity.
  • Avelumab (Merck, Germany) was administered intraperitoneally at a dose of 10 mg/kg (Q2D x 2 times), and Avelumab and Aldesleukin were administered in combination (Aldesleukin 0.46 mg/kg, QD x 5 times, ip+ Avelumab 10 mg /kg, Day 5, 7, ip,).
  • Figure 2a shows the results of comparing the anticancer activity of the PD-L1 antibody-IL2 variant 2 protein complex according to one embodiment and the positive control group.
  • Figure 2b shows the results of confirming the individual cancer cell growth inhibition effect and complete remission activity of the PD-L1 antibody-IL2 variant 2 protein complex according to one embodiment on colon cancer transplanted mice.
  • Figure 2c shows the results confirming the cancer cell growth inhibition effect and complete remission activity of the negative control group and the positive control group (Avelumab and combined administration of Avelumab and Aldesleukin) on mice transplanted with colon cancer.
  • the tumor volume of the negative control group (vehicle) and the positive control group increased over time after administration, while the PD-L1 antibody-IL2 variant 2 prepared in Example 3-2
  • the protein complex exhibits a strong cancer cell growth inhibitory effect. Specifically, it was confirmed that most tumors disappeared at a dose of 16 mg/kg of the PD-L1 antibody-IL2 variant 2 protein complex.
  • the PD-L1 antibody-IL2 comparison group protein complex in the case of the PD-L1 antibody-IL2 variant 2 protein complex, no body weight loss or death occurred regardless of the administered dose.
  • the tumor volume of the negative control group and the positive control group increased over time after administration, and the mice showing complete response (CR) were tested in 10 mice of the same administration group. It was confirmed that there were relatively few animals, 0 to 2.
  • the number of mice showing complete remission increased to 6 to 9 out of 10 experimental animals in the same administration group in a dose-dependent manner, compared to the negative and positive control groups. It was confirmed that it exhibits significant anticancer activity.
  • the PD-L1 antibody-IL2 variant protein complex exhibits superior anticancer activity compared to the existing antibody treatment Avelumab and/or the combined administration of Avelumab and Aldesleukin.
  • the anticancer activity of the PD-L1 antibody-IL2 variant protein complex according to one aspect was confirmed.
  • Figure 3 shows the results of confirming the anticancer activity of the PD-L1 antibody-IL2 variant 4 protein complex according to one embodiment.
  • the tumor volume of the negative control group increased over time after administration, while the PD-L1 antibody-IL2 variant 4 protein complex prepared in Example 3-2 It was confirmed that it had a strong cancer cell growth inhibitory effect compared to the negative control group.
  • the PD-L1 antibody-IL2 variant 4 protein complex showed a significantly smaller change in tumor volume at doses of 8 mg/kg and 16 mg/kg compared to the positive control group administered at a dose of 10 mg/kg. I was able to confirm.
  • the mouse showing complete remission was 1 out of 10 experimental animals in the same administration group, whereas in the case of the PD-L1 antibody-IL2 variant 4 protein complex, 4 to 5 out of 10 experimental animals in the same administration group It was confirmed that the anticancer activity increased significantly compared to the positive control group.
  • the PD-L1 antibody-IL2 variant protein complex selectively increases the activity of effector T cells compared to regulatory T cells compared to existing immunotherapy anticancer antibody treatments, thereby preventing or treating various immune diseases, including cancer. It can be usefully used.
  • the PD-L1 antibody-IL2 variant protein complex not only has excellent anticancer activity, but also reduces side effects caused by IL2, thereby providing a safer treatment compared to existing immunotherapy treatments for cancer.
  • Anti-mousePD-1 Fab-Fc (hereinafter referred to as “a”) was produced in the same manner as in Example 3-1, except that the PD-1 antibody and IL2 variants 1 and 4 prepared in Example 1 were used.
  • the mousePD-1 antibody-IL2 variant protein complex (a+b) obtained through culturing the cell line prepared in Example 4-1 was purified in the same manner as in Example 3-2 to obtain a highly purified material.
  • Example 4-2 To confirm the effect of the mousePD-1 antibody-IL2 variant protein complex (a+b) obtained in Example 4-2 on the activation of human immune cells, an experiment was performed in the same manner as Example 3-4. .
  • the IL2 variant protein maintains its original characteristics even when complexed with PD-L1 antibodies as well as other immune checkpoint inhibitors and can participate in the immune response by promoting the activity of effector T cells. Able to know.
  • Protein complexes containing the mousePD-1 antibody and IL2 variants 1, 2, 3, 4, 7, 8, 14, and 15 were prepared. Specifically, a polynucleotide encoding the mousePD-1 antibody heavy chain variable region-constant region and a polynucleotide encoding the mousePD-1 antibody light chain constant region-light chain variable region were synthesized using the Invitrogen GeneArt Gene Synthesis service of ThermoFisher Scientific, respectively. . Thereafter, each of the above polynucleotides was inserted into the AvrII-Bstz17I enzyme site and EcoRV-PacI enzyme site of the pCHO1.0 expression vector, respectively, to prepare a first expression vector expressing the mousePD-1 antibody.
  • any one of the IL2 variants 1, 2, 3, 4, 7, 8, 14 and 15 of Example 1 above was added to the C terminus of the polynucleotide encoding the mousePD-1 antibody heavy chain variable region-constant region.
  • a polynucleotide encoding a complex containing a linker was synthesized and inserted into the AvrII-BstZ17I enzyme site of the pCHO1.0 expression vector, and the mouse PD-1 antibody light chain constant region-light chain variable region was inserted into the EcoRV-PacI enzyme site.
  • a second expression vector was prepared.
  • Example 2-1 a protein complex containing anti-mousePD-1 Fab-Fc (a) and anti-mousePD-1 Fab-Fc-C terminal IL2 variant (hereinafter referred to as “c”) was prepared ( a+c) was obtained (see Figure 4b).
  • the mousePD-1 antibody-IL2 variant protein complex (a+c) obtained through culturing the cell line prepared in Example 5-1 was purified to obtain a high purity material (purity of 98% or more).
  • Example 3-2 fine debris was removed in the same manner as Example 3-2, except that the mousePD-1 antibody-IL2 variant protein complex (a+c) was used, and then primary purification was performed. Afterwards, the filtered medium was added to the Protein A column stabilized with Phosphate buffer saline (pH 7.4), and non-specifically bound proteins were washed away using the same buffer, followed by 0.05 M Citric acid (pH 5.0). It was washed once more using a buffer solution containing . Afterwards, the protein that specifically binds to the Protein-A column was eluted using a pH descending gradient using 0.02 M Citric acid (pH 5.0 and pH 3.5), and the sample was neutralized to pH 7.2 using 1 M Tris.
  • Phosphate buffer saline pH 7.4
  • Citric acid pH 5.0
  • the sample separated through the affinity column was subjected to secondary purification using a hydrophobic interaction column (Phenyl HP, Cytiva) to remove impurities derived from the remaining substances.
  • a hydrophobic interaction column Phenyl HP, Cytiva
  • 1 M Citric acid was added to the Phenyl HP column stabilized with 0.02 M sodium phosphate (pH 7.0) buffer and 0.8 M Ammonium sulfate (pH 7.0), and the sample eluted and neutralized from the Protein-A column was adjusted to pH 7.0. After titration, proteins that did not bind non-specifically were washed away using the same buffer.
  • mousePD-1 antibody-IL2 variant protein complex (a+c) was obtained by eluting with a descending salt concentration gradient using a buffer solution containing 0.02 M sodium phosphate (pH 7.0).
  • the obtained mousePD-1 antibody-IL2 variant protein complex (a+c) was stabilized with Phosphate buffer saline (pH 7.4), and purity was checked using size exclusion HPLC (TSK-3000SWxL, 7.8 mm x 30 cm, Tosoh). Analysis was performed.
  • Figure 5a shows the results of purifying the mousePD-1 antibody-IL2 variant 14 protein complex (a+c) according to one embodiment using the Protein-A affinity column purification method.
  • Figure 5b shows the results of purifying the mousePD-1 antibody-IL2 variant 14 protein complex (a+c) according to one embodiment using a hydrophobic interaction column purification method.
  • Figure 5c shows the results of purity analysis of mousePD-1 antibody-IL2 variant 14 protein complex (a+c) according to one embodiment.
  • the protein that specifically binds to the column was confirmed by the elution buffer used in Protein-A affinity column purification.
  • the mousePD-1 antibody-IL2 variant 14 protein complex (a+c) that specifically bound to the column was confirmed in 2800 to 2900 ml of the eluate.
  • mousePD-1 antibody-IL2 variant 14 protein complex (a+c) obtained through all purification processes was confirmed to have a purity of 98.6% at a retention time of 15.639 minutes.
  • mousePD-1 antibody-IL2 variant protein complex (a+c) according to one aspect is purified with high purity.
  • micePD-1 antibody-IL2 variant 1 protein complex (a+c) and the mousePD-1 antibody-IL2 variant 14 protein complex (a+c) prepared in Example 5-2 were mixed at a concentration range of 1.56 to 8000 nM.
  • the receptor binding ability of the mousePD-1 antibody-IL2 variant protein complex (a+c) was confirmed in the same manner as in Example 3-3, except that the development was carried out by serial dilution.
  • the mousePD-1 antibody-IL2 variant 1 protein complex (a+c) and the mousePD-1 antibody-IL2 variant 14 protein complex (a+c) are 5,610 nM and 6,290 nM, respectively, for IL2Rb.
  • a binding affinity of nM it was confirmed that binding was performed at a similar level.
  • the binding affinity with IL2Rbg was 4.51 nM and 35.3 nM, respectively, in the mousePD-1 antibody-IL2 variant 14 protein complex (a+c) compared to the mousePD-1 antibody-IL2 variant 1 protein complex (a+c). It was confirmed that the binding force was reduced by about 7.8 times.
  • mousePD-1 antibody-IL2 variant 1 protein complex (a+c) and mousePD-1 antibody-IL2 variant 14 protein complex (a+c) have similar binding affinity to IL2Rb. This means that the binding affinity for IL2Rg of the mousePD-1 antibody-IL2 variant 14 protein complex (a+c) was reduced by about 7.8 times compared to the complex (a+c).
  • mousePD-1 antibody-IL2 variant 1 protein complex mousePD-1 antibody-IL2 variant 2 protein complex, mousePD-1 antibody-IL2 variant 3 protein complex, mousePD-1 antibody-IL2 variant 4 prepared in Example 5-2. protein complex, mousePD-1 antibody-IL2 variant 7 protein complex, mousePD-1 antibody-IL2 variant 8 protein complex, mousePD-1 antibody-IL2 variant 14 protein complex, and mousePD-1 antibody-IL2 variant 15 protein complex with mousePD-1
  • the effect of the mousePD-1 antibody-IL2 variant protein complex (a+c) on the activation of human immune cells was confirmed in the same manner as Example 3-4, except that the antibody-IL2 variant comparison group was used. did.
  • the ratio of the EC 50 value of CD8 + T cells / regulatory T cells was 21.4, while the mousePD-1 antibody prepared in Example 5-2 -
  • the range was 0.5 to 1.2.
  • the positive control group activates regulatory T cells more strongly
  • the mousePD-1 antibody-IL2 variant protein complex (a+c) according to one embodiment selectively activates CD8+ T cells, which are effector T cells, rather than regulatory T cells. You can see that it is done. In other words, it can be seen that the IL2 variant maintains its unique characteristic of selectively activating CD8+ T cells even in a structure connected to the C terminus of the FC region.
  • the activity of the mousePD-1 antibody-IL2 variant 1 protein complex (a+c) against T regs and CD8+ T cells was 11.91 ⁇ 8.02 nM and 9.61 ⁇ 1.44 nM, respectively, whereas the mousePD-1 antibody-IL2 variant 14 protein complex
  • the activity of the complex (a+c) against T regs and CD8+ T cells was 320.7 ⁇ 279.1 nM and 161.1 ⁇ 70.3 nM, respectively, compared to the mousePD-1 antibody-IL2 variant 1 protein complex (a+c). 1 It was confirmed that the activity of antibody-IL2 variant 14 protein complex (a+c) on T reg and CD8+ T cells was decreased.
  • the mousePD-1 antibody-IL2 variant protein complex (a+c) may participate in an immune response related to an anticancer effect by selectively activating effector T cells compared to regulatory T cells.
  • mice MC38 cells (1.0 model) was manufactured. Afterwards, when the tumor size in the mouse reached about 70-120 mm3, 3-6 mice were divided into each drug administration group, and then the mousePD-1 antibody-IL2 variant 14 protein complex (a+) prepared in Example 5-2 was added to the mouse. c) was administered intraperitoneally twice in doses of 1, 3, 5, and 10 mg/kg, once a week. At this time, a vehicle was used as a negative control, and 3 mg/kg of anti-PD1 antibody J43 (clone) and 3 mg/kg of J43 + IL2 comparison group-Fc complex 1.4 mg/kg were used as positive controls. Thereafter, the tumor growth inhibition effect by drug administration was observed until 19 days after the first drug administration.
  • Figure 6a shows the results of comparing the anticancer activity of mousePD-1 antibody-IL2 variant 14 protein complex (a+c), negative control group, and positive control group according to one embodiment in a colon cancer transplant mouse model.
  • Figure 6b shows the results of comparing the change in body weight of the colon cancer transplant mouse model according to the anticancer activity of the mousePD-1 antibody-IL2 variant 14 protein complex (a+c), negative control group, and positive control group according to one embodiment.
  • the tumor volume of the negative control group and the positive control group increased over time, while the mousePD-1 antibody-IL2 variant 14 protein complex prepared in Example 5-2 ( It was confirmed that a+c) exhibited a cancer cell growth inhibitory effect in a dose-dependent manner compared to immediately after administration.
  • a+c exhibited a cancer cell growth inhibitory effect in a dose-dependent manner compared to immediately after administration.
  • the positive control group and the combined administration group it was confirmed that when 5 mg/kg and 10 mg/kg of the mousePD-1 antibody-IL2 variant 14 protein complex (a+c) was administered, an excellent cancer cell growth effect was observed. . That is, it was confirmed that the mousePD-1 antibody-IL2 variant 14 protein complex (a+c) had significantly superior anticancer activity compared to the case of combined administration of PD-1 single antibody and IL2 comparison group-Fc protein complex.
  • the mousePD-1 antibody-IL2 variant protein complex (a+c) specifically activates effector T cells compared to existing immunotherapy treatments for cancer, and is used for the prevention or treatment of various immune diseases related to cancer. It can be useful.
  • Protein complexes containing humanPD-1 antibody and IL2 comparison group, IL2 variant 1, and IL2 variant 14 were prepared, respectively. Specifically, Example 5-1 above, except that a polynucleotide encoding the humanPD-1 antibody heavy chain variable region-constant region and a polynucleotide encoding the humanPD-1 antibody light chain constant region-light chain variable region were used. In the same way, a protein complex (A +C) was obtained.
  • the humanPD-1 antibody-IL2 variant protein complex (A+C) obtained through culturing the cell line prepared in Example 6-1 was purified in the same manner as in Example 5-2, and then purified in Phosphate buffer saline (pH 7.4). ) to secure high purity humanPD-1 antibody-IL2 variant protein complex (A+C). Thereafter, purity analysis was performed in the same manner as in Example 5-2.
  • humanPD-1 antibody-IL2 comparison group protein complex A+C
  • humanPD-1 antibody-IL2 variant 1 protein complex A+C
  • humanPD-1 antibody-IL2 variant 14 protein prepared in Example 6-2 The humanPD-1 antibody-IL2 variant protein complex (A + The receptor binding capacity of C) was confirmed.
  • Pembrolizumab was used as a positive control for human PD-1
  • humanPD-1 antibody-IL2 variant 1 was used as a control, and the results are shown in Tables 10 and 11 below.
  • Ligand experimental group Binding affinity (KD, nM) hPD-1 Pembrolizumab 2.70 huPD-1 antibody-IL2 comparison group protein complex 2.95 huPD-1 antibody-IL2 variant 1 protein complex 2.25 huPD-1 antibody-IL2 variant 14 protein complex 2.60
  • Binding affinity (nM, SPR analysis) Human IL2R ⁇ Human IL2R ⁇ Human IL2R ⁇ Human IL2R ⁇ huPD-1 antibody-IL2 comparison group protein complex 105 6.506 3.08 0.023 huPD-1 antibody-IL2 variant 1 protein complex No binding 5.462 2.92 0.782 huPD-1 antibody-IL2 variant 14 protein complex No binding 5.611 68.3 25.5 huPD-1 antibody-IL2 variant 14/ huPD-1 antibody-IL2 variant 1 (Bonding force relative ratio) - 1.03 23.4 32.6
  • humanPD-1 antibody-IL2 variant 1 protein complex (A+C) and humanPD-1 antibody-IL2 variant 14 protein complex (A+C) do not react with IL2R ⁇ . I was able to confirm.
  • humanPD-1 antibody-IL2 variant 1 protein complex (A+C) and humanPD-1 antibody-IL2 variant 14 protein complex (A+C) showed similar binding affinities of 5.462 nM and 5.611 nM, respectively.
  • the humanPD-1 antibody-IL2 variant 1 protein complex (A+C) and the humanPD-1 antibody-IL2 variant 14 protein complex (A+C) have binding affinities of 2.92 nM and 68.3 nM, respectively, for IL2R ⁇ .
  • the binding affinity of the humanPD-1 antibody-IL2 variant 14 protein complex (A+C) to IL2R ⁇ is similar to that of the humanPD-1 antibody-IL2 variant 1 protein complex (A+C), while the binding affinity to IL2R ⁇ is similar to that of the humanPD-1 antibody-IL2 variant 1 protein complex (A+C). It can be seen that the binding force decreases. Specifically, it was confirmed that the binding affinity of the humanPD-1 antibody-IL2 variant 14 protein complex (A+C) to IL2R ⁇ and IL2R ⁇ was reduced by about 23.4- and 32.6-fold, respectively, compared to the humanPD-1 antibody-IL2 variant 1.
  • the humanPD-1 antibody-IL2 variant protein complex (A+C) according to one aspect is intended to induce high activation in CD8+ T cells compared to regulatory T cells, and selective activation of CD8+ T cells expressing IL2R ⁇ .
  • the binding affinity to IL2R ⁇ is removed and the binding affinity to IL2R ⁇ is regulated through substitution of specific amino acids.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PCT/KR2023/012348 2022-08-23 2023-08-21 Il2 변이체 및 이를 포함하는 단백질 복합체 Ceased WO2024043643A1 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP23857675.5A EP4578871A1 (en) 2022-08-23 2023-08-21 Il2 variant and protein complex comprising same
AU2023330441A AU2023330441A1 (en) 2022-08-23 2023-08-21 Il2 variant and protein complex comprising same
CN202380061464.0A CN119790064A (zh) 2022-08-23 2023-08-21 Il2变体和包括该il2变体的蛋白复合体
JP2025511613A JP2025527694A (ja) 2022-08-23 2023-08-21 Ｉｌ２変異体及びそれを含むタンパク質複合体

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20220105643 2022-08-23
KR10-2022-0105643 2022-08-23
KR20230057361 2023-05-02
KR10-2023-0057361 2023-05-02

Publications (1)

Publication Number Publication Date
WO2024043643A1 true WO2024043643A1 (ko) 2024-02-29

Family

ID=90013668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/012348 Ceased WO2024043643A1 (ko) 2022-08-23 2023-08-21 Il2 변이체 및 이를 포함하는 단백질 복합체

Country Status (6)

Country Link
EP (1) EP4578871A1 (https=)
JP (1) JP2025527694A (https=)
KR (1) KR102655850B1 (https=)
CN (1) CN119790064A (https=)
AU (1) AU2023330441A1 (https=)
WO (1) WO2024043643A1 (https=)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180117116A (ko) * 2016-02-05 2018-10-26 워싱턴 유니버시티 표적화된 사이토카인 전달을 위한 조성물 및 방법들
KR20190057113A (ko) * 2016-09-28 2019-05-27 조마 (유에스) 엘엘씨 인터루킨-2에 결합하는 항체 및 그 용도
KR20190121816A (ko) * 2017-04-03 2019-10-28 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
WO2020057646A1 (zh) * 2018-09-21 2020-03-26 信达生物制药(苏州)有限公司 新型白介素2及其用途
KR20200100098A (ko) * 2017-12-19 2020-08-25 젠코어 인코포레이티드 조작된 il-2 fc 융합 단백질
KR20210098148A (ko) * 2020-01-31 2021-08-10 주식회사 제넥신 항-taa 항체, 항-pd-l1 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
KR20220105643A (ko) 2019-10-25 2022-07-27 오덴테스 테라퓨틱스, 인크. 글리코겐 축적 장애를 치료하기 위한 조성물 및 방법
KR20230057361A (ko) 2020-08-26 2023-04-28 레벤타스 리미티드 플라스틱 재활용 개선 또는 그 관련사항

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234205A1 (en) * 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
AU2013258834B2 (en) * 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
DK3186283T3 (da) * 2014-08-29 2020-03-02 Hoffmann La Roche Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1
EP3504234A4 (en) * 2016-09-29 2020-12-02 Beijing Hanmi Pharmaceutical Co., Ltd. CONSTRUCTIONS OF HETERODIMERIC IMMUNOGLOBULINS AND THEIR PREPARATION PROCESSES
CU24483B1 (es) * 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
CN118271419A (zh) * 2020-03-31 2024-07-02 韩美药品株式会社 新型免疫刺激il-2类似物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180117116A (ko) * 2016-02-05 2018-10-26 워싱턴 유니버시티 표적화된 사이토카인 전달을 위한 조성물 및 방법들
KR20190057113A (ko) * 2016-09-28 2019-05-27 조마 (유에스) 엘엘씨 인터루킨-2에 결합하는 항체 및 그 용도
KR20190121816A (ko) * 2017-04-03 2019-10-28 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
KR20200100098A (ko) * 2017-12-19 2020-08-25 젠코어 인코포레이티드 조작된 il-2 fc 융합 단백질
WO2020057646A1 (zh) * 2018-09-21 2020-03-26 信达生物制药(苏州)有限公司 新型白介素2及其用途
KR20220105643A (ko) 2019-10-25 2022-07-27 오덴테스 테라퓨틱스, 인크. 글리코겐 축적 장애를 치료하기 위한 조성물 및 방법
KR20210098148A (ko) * 2020-01-31 2021-08-10 주식회사 제넥신 항-taa 항체, 항-pd-l1 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
KR20230057361A (ko) 2020-08-26 2023-04-28 레벤타스 리미티드 플라스틱 재활용 개선 또는 그 관련사항

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL IMMUNOLOGY, vol. 18, no. 10, 2006, pages 1461 - 1471
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE
NATURE REVIEW IMMUNOLOGY., vol. 12, 2012, pages 180 - 190

Also Published As

Publication number Publication date
JP2025527694A (ja) 2025-08-22
KR20240028310A (ko) 2024-03-05
AU2023330441A1 (en) 2025-02-20
EP4578871A1 (en) 2025-07-02
CN119790064A (zh) 2025-04-08
KR102655850B1 (ko) 2024-04-11

Similar Documents

Publication Publication Date Title
WO2015133817A1 (ko) B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
WO2018217058A1 (en) Anti-human interleukin-2 antibodies and uses thereof
WO2018030806A1 (ko) 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물
WO2017030370A1 (ko) 항-코티닌 항체가 연결된 키메라 항체 수용체 및 이의 용도
WO2019203600A1 (ko) 스위치 분자 및 스위처블 키메라 항원 수용체
WO2020005003A1 (ko) Lag-3에 특이적으로 결합하는 단클론항체 및 이의 용도
WO2022124866A1 (ko) 항-pd-1 항체 및 이의 용도
WO2022169269A1 (ko) 항 ctla-4 항체 및 이의 용도
WO2021107689A1 (ko) Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 면역관문 억제제를 포함하는 암 치료용 약학 조성물
WO2022035200A1 (ko) Il-12 및 항-cd20 항체를 포함하는 융합단백질 및 이의 용도
WO2021235697A1 (ko) Cd22에 특이적인 항체 및 이의 용도
WO2018026248A1 (ko) 프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도
WO2020004937A1 (ko) 항-bcma 항체-약물 접합체 및 그 용도
WO2021235696A1 (ko) Cd22에 특이적인 항체 및 이의 용도
WO2023224429A1 (ko) Light 단백질 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도
WO2021101349A1 (ko) Ror1 및 b7-h3에 결합하는 항체, 이를 포함하는 항체-약물 접합체 및 그 용도
WO2024172363A1 (ko) 항-cntn4 항체 및 그의 용도
WO2024043643A1 (ko) Il2 변이체 및 이를 포함하는 단백질 복합체
WO2021153979A1 (ko) 항-taa 항체, 항-pd-l1 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
WO2022145739A1 (en) Humanized antibody specific for cd22 and chimeric antigen receptor using the same
WO2021246720A1 (ko) 이중특이 항체 또는 그의 항원-결합 단편 및 이를 제조하는 방법
WO2024112133A1 (en) Cassette for expression of fusion protein from which methionine at the n-terminus has been removed, and use thereof
WO2023249425A1 (ko) 항-cd73 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
WO2024191168A1 (ko) 신규한 cd3 결합항체 및 이를 포함한 다중특이 항체
WO2025188047A1 (en) Anti-lilrb4 antibodies and anti-lilrb4/anti-4-1bb bispecific antibodies and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23857675

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: AU2023330441

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2023330441

Country of ref document: AU

Date of ref document: 20230821

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025511613

Country of ref document: JP

Ref document number: 202380061464.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2023857675

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023857675

Country of ref document: EP

Effective date: 20250324

WWP Wipo information: published in national office

Ref document number: 202380061464.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2023857675

Country of ref document: EP